

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ASCENTAGE PHARMA GROUP INTERNATIONAL

亞盛醫藥集團

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6855)

CLARIFICATION ANNOUNCEMENT

Reference is made to the Next Day Disclosure Return of Ascentage Pharma Group International (the “**Company**”) published on 25 November 2020.

The Company would like to clarify that the date of adoption of the Pre-IPO Share Option Scheme in the Next Day Disclosure Return should be “July 13, 2018” instead of “September 28, 2019”.

Save as the clarification above, all other information in the Next Day Disclosure Return shall remain unchanged.

By order of the Board
Ascentage Pharma Group International
Dr. Yang Dajun
Chairman and Executive Director

Suzhou, People’s Republic of China, November 30, 2020

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Yang Dajun as Chairman and Executive Director, Dr. Wang Shaomeng, Dr. Tian Yuan, Mr. Zhao Qun, Dr. Lu Simon Dazhong and Mr. Liu Qian as Non-executive Directors, and Mr. Ye Changqing, Dr. Yin Zheng and Mr. Ren Wei as Independent Non-executive Directors.